Shareholder Information
Shareholder Meetings
| Date | Title | Downloads |
|---|---|---|
| Mar 19 2021 | 2021 AGM Notice and Proxy Statement | |
| Dec 18 2020 | 2020 General Meeting Notice | |
| Apr 07 2020 | 2020 AGM Notice | |
| Mar 22 2019 | 2019 AGM Notice |
AGM 2021
| Resolution | Votes For | % of Shares Voted | Votes Against | % of Shares Voted | Votes Withheld |
|---|---|---|---|---|---|
| 1. Re-election of David Ebsworth | 437,364,357 | 99.996 | 19,404 | 0.004 | 693,872 |
| 2. Re-election of Martin Edwards | 438,029,801 | 99.995 | 20,504 | 0.005 | 27,328 |
| 3. Re-election of Anders Ullman | 438,031,225 | 99.996 | 19,080 | 0.004 | 27,328 |
| 4. Re-election of Lisa Deschamps | 437,987,653 | 99.986 | 62,652 | 0.014 | 27,328 |
| 5. Adoption of UK Annual Accounts | 438,049,233 | 99.997 | 14,032 | 0.003 | 14,368 |
| 6. Approval of UK Directors’ Remuneration Report | 437,440,863 | 99.857 | 624,250 | 0.143 | 12,520 |
| 7. Approval of UK Directors’ Remuneration Policy | 437,393,559 | 99.850 | 658,754 | 0.150 | 25,320 |
| 8. Re-appointment of auditor | 438,048,059 | 99.996 | 19,270 | 0.004 | 10,304 |
| 9. Remuneration of auditor | 438,030,613 | 99.994 | 27,780 | 0.006 | 19,240 |
| 10. Authority to allot shares | 397,293,901 | 90.697 | 40,753,252 | 9.303 | 30,480 |
| 11. Disapplication of pre-emption rights | 397,273,909 | 90.696 | 40,756,452 | 9.304 | 47,272 |
A “Withheld” vote is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution
PFIC Annual Information Statement
| Date | Title | Downloads |
|---|---|---|
| Jan 25 2021 | 2020 PFIC Annual Information Statement |
On which stock exchanges are Verona’s shares traded and what are the ticker symbols?
Verona Pharma’s shares are listed on The NASDAQ Global Market under the symbol “VRNA”.
How can I purchase shares?
Shares can be purchased through a stockbroker of your choice.
Who is Verona Pharma's transfer agent and how do I contact them?
The Company shares are listed on The Nasdaq Global Market in the form of American Depository Shares (ADSs). The transfer agent for ADSs is Citigroup. You can contact them as follows:
Citigroup
Depositary Services
388 Greenwich Street
New York
NY 10013
Email: citiadr@citi.com
How can I replace my lost stock certificates?
Please contact our transfer agent, the details of which are provided above. There is a fee for replacing lost certificates.
How do I report a change of mailing address?
You must send both your old and new addresses to our transfer agent, the details of which are provided above. Each stockholder in question must sign the request for an address change.
Where is Verona Pharma's registered office?
Verona Pharma plc is registered in England and Wales under company number is 5375156 and its registered office is at One Central Square, Cardiff CF10 1FS, Wales, United Kingdom. Our VAT number is 919163219. The Company's principal office is in central London. The Company's US office is in North Carolina.
Where can I find out more about Verona Pharma's R&D programs?
You can view information on our platform and programs by visiting the Product Pipeline section of our website.
How can I participate in Verona Pharma's clinical studies?
You should contact your physician to discuss if you are eligible to join.
Where can I get the latest corporate news releases and financial reports?
You can view our recent press releases by visiting the Media section of our website.
How can I obtain further information or materials on Verona Pharma?
More information can be found on the Verona Pharma website and the SEC website.
Whom should I contact regarding investor inquiries?
All Company updates disclosed to the market can be found here. Alternatively, you can register to receive updates announced by the Company by subscribing to our Email Alerts here. For specific Investor Relations or Media enquiries, please contact our Investor Relations Advisers, Argot Partners (US enquiries) or Optimum Strategic Communications (European enquiries).
Argot Partners
767 Third Avenue
34th Floor
New York
NY10017
verona@argotpartners.com
+1-212-600-1902
Optimum Strategic Communications
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
verona@optimumcomms.com
+44 (0)203 950 9144
Verona Pharma
Investor Information
© Verona Pharma plc 2021. All rights reserved